Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

10:55 AM ET 10-Q
Financial Results M/I Homes, Inc. MHO

M/I Homes Q3 2026 Results: Net Income $66.6M, Down 37.5% YoY

M/I Homes, Inc. reported its quarterly financial results for the period ended September 30, 2026, highlighting its performance in residential homebuilding and mortgage banking. The filing details the company's operational results, including home deliveries, new contracts, and land development activities.

Key figure
Net income $66.6M · -37.5% YoY
10:54 AM ET 8-K
Clinical Trial Data Perspective Therapeutics, Inc. CATX

Perspective Therapeutics Clinical Trial Data

Perspective Therapeutics announced updated interim Phase 1/2a results for [212Pb]VMT-α-NET in patients with SSTR2-expressing neuroendocrine tumors, showing objective response rates of 33% and 50% in Cohorts 2 and 3, respectively. The data demonstrated a 72% progression-free survival rate at 18 months with no dose-limiting toxicities, supporting the company's plan to initiate Phase 3 trials in 2027.

10:32 AM ET 8-K
M&A Deal Bolt Biotherapeutics, Inc. BOLT

Bolt Biotherapeutics M&A Deal with Prana Therapies, Inc.

Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger, issuing common and Series D preferred stock to Prana shareholders. Following the merger and a concurrent $120 million private placement, former Prana equityholders will own approximately 51.7% of the combined company. The transaction shifts Bolt's focus to Prana's INSPIRE platform and its lead bispecific antibody candidate, PRA-216, for inflammatory diseases.

Counterparty
Prana Therapies, Inc.
10:15 AM ET 10-Q
Financial Results Synera Studio Inc

Synera Studio Q1 2026 Results: Net Loss of $3.34K, Loss Widens

Synera Studio Inc reported revenue of $28,690 for the quarter ended September 30, 2026, compared to $5,000 in the prior year period, though it incurred a net loss of $3,341. The company capitalized $70,380 in software development costs and issued 1,110,000 shares of common stock for cash proceeds of $22,200 during the period.

Key figure
Net loss $3.34K
10:00 AM ET 8-K
Capital Raise ExchangeRight Income Fund

ExchangeRight Income Fund Capital Raise

ExchangeRight Income Fund sold 16,740 Class D Common Shares for gross proceeds of $462,000 between October 8 and October 21, 2026. The sale is part of an ongoing continuous private placement offering of up to $2.165 billion in common shares.

9:49 AM ET 8-K
Dividend Sb Financial Group, Inc. SBFG

Sb Financial Group Dividend

SB Financial Group, Inc. declared a quarterly cash dividend of $0.165 per common share. The dividend is payable on November 27, 2026, to shareholders of record as of November 13, 2026, representing a 6 percent increase over the prior year's quarterly dividend.

9:47 AM ET Form 4
Insider Selling Pimco Dynamic Income Strategy Fund PDX

Pimco Dynamic Income Strategy Fund Insider Saba Capital Management L.P. Sells $77.9K of Stock

Saba Capital Management L.P. sold 3,800 shares of Pimco Dynamic Income Strategy Fund at $20.47 to $20.50 a share (average $20.49) in 2 transactions, worth $77.9K in total on Oct 21, 2026. Shares held after the trade: 6,022,547 (-0.0%).

Value
$77.9K
Shares
3,800
Average price
$20.49
Holding change
-0.0%
Trade date
Oct 21, 2026
9:42 AM ET 10-Q
Financial Results Autoliv Inc ALV

Autoliv Q3 2026 Results: Net Income $155M, Down 11.4% YoY

For the nine months ended September 30, 2026, Autoliv reported net sales of $8,249 million, a slight increase from $7,998 million in the prior year, though net income attributable to controlling interest decreased to $397 million from $509 million. The company engaged in significant capital returns, including $350 million in stock repurchases and $192 million in dividends paid during the first three quarters of 2026.

Key figure
Net income $155M · -11.4% YoY
9:34 AM ET 8-K
Loan & Debt Mercedes-Benz Auto Lease Trust 2026-B

Mercedes-Benz Auto Lease Trust 2026-B Debt Financing Update with U.S. Bank Trust Company, National Association

Mercedes-Benz Auto Lease Trust 2026-B completed the issuance of Asset Backed Notes on October 22, 2026. In connection with the issuance, the trust entered into an indenture and several related credit and servicing agreements to secure the obligations of the Titling Trust and the Initial Secured Party.

Counterparty
U.S. Bank Trust Company, National Association
9:29 AM ET Form 4
Insider Buying Cleveland-Cliffs Inc. CLF

Cleveland-Cliffs Insider Edilson Camara Buys $99.8K of Stock

Edilson Camara bought 7,400 shares of Cleveland-Cliffs Inc. at $13.49 a share, worth $99.8K in total on Oct 22, 2026. Shares held after the trade: 64,717 (+12.9%).

Value
$99.8K
Shares
7,400
Price
$13.49
Holding change
+12.9%
Trade date
Oct 22, 2026
9:26 AM ET 8-K
Financial Results BV Financial, Inc. BVFL

BV Financial Financial Results

BV Financial, Inc. reported Q3 2026 net income of $3.4 million, or $0.42 per diluted share, compared to $3.7 million in the prior year period. The company highlighted a decrease in total assets to $877.9 million as it utilized loan portfolio cash to repay $30.0 million in FHLB borrowings, while also repurchasing 163,540 shares during the quarter.

Term
Q3 2026
9:24 AM ET 8-K
Financial Results Tompkins Financial Corp TMP

Tompkins Financial Financial Results

Tompkins Financial Corporation reported Q3 2026 net income of $28.7 million, or $2.00 per diluted share, representing a 21.2% increase in EPS compared to the same period in 2025. The results were driven by a 21.0% year-over-year increase in net interest income and expansion of the net interest margin to 3.65%. Additionally, the company's Board of Directors declared a quarterly dividend of $0.74 per share, a 13.8% increase over the prior year's fourth quarter dividend.

Term
Q3 2026

“We are pleased to report strong financial results for the third quarter. Our consistent levels of loan and deposit growth along with further expansion in net interest margin continue to provide momentum as we look forward. Given our strength in earnings and capital position we have approved another dividend increase, payable in the fourth quarter of 2026. This dividend represents a 13.8% increase compared to the dividend paid in the fourth quarter of 2025.”

Stephen Romaine, President and CEO
9:19 AM ET 8-K
Reverse Stock Split Nuwellis, Inc. NUWE

Nuwellis Reverse Stock Split

Nuwellis, Inc. has announced a 1-for-9 reverse stock split of its issued and outstanding common stock, effective October 26, 2026. The split-adjusted shares will begin trading on the Nasdaq Capital Market under the existing symbol 'NUWE' on October 27, 2026. This action consolidates every nine shares into one share to adjust the company's capital structure.

9:15 AM ET 8-K
Clinical Trial Data Eikon Therapeutics, Inc. EIKN

Eikon Therapeutics Clinical Trial Data

Eikon Therapeutics presented initial and updated Phase 1/2 clinical data for its PARP1-selective inhibitors (EIK1003, EIK1004) and WRN helicase inhibitor (EIK1005) at the 2026 ESMO Congress. EIK1003 monotherapy showed a 31.3% objective response rate in PARP-naïve patients with HRR-mutated tumors, while EIK1004 and EIK1005 demonstrated favorable safety and tolerability profiles in early dose-escalation cohorts.

“These data strengthen the foundation of our clinical-stage pipeline, with encouraging evidence of activity and tolerability across our selective PARP1 programs. The EIK1003 results support continued development both as monotherapy and in combination with established cancer treatments, while the initial EIK1004 findings support further evaluation of our CNS-penetrant PARP1 inhibitor. The first clinical results for EIK1005, our internally derived WRN helicase inhibitor, mark an important step in translating Eikon’s discovery science into potential new medicines for patients.”

Roy Baynes, M.D., Ph.D., Chief Medical Officer of Eikon
9:15 AM ET 8-K
Financial Results Gorman Rupp Co GRC

Gorman Rupp Financial Results

The Gorman-Rupp Company reported record third quarter 2026 financial results, with net sales increasing 11.8% to $193.3 million. Net income rose significantly to $22.7 million, or $0.86 per share, driven by volume growth, price increases, and improved operating leverage across all markets.

Term
Q3 2026
9:04 AM ET 8-K
Loan & Debt Walmart Inc. WMT

Walmart $3B Debt Financing with BNP Paribas Securities Corp.

Walmart Inc. entered into pricing agreements to issue $3.0 billion in aggregate principal amount of senior notes across four tranches with maturities ranging from 2029 to 2036. Additionally, the company announced a multi-tranche offering of Canadian-dollar denominated notes totaling C$5.0 billion. The proceeds from these debt issuances are intended for general corporate purposes.

Value
$3B
Counterparty
BNP Paribas Securities Corp., BofA Securities, Inc., Morgan Stanley & Co. LLC, Citigroup Global Markets Inc., Goldman Sachs & Co. LLC and Wells Fargo Securities, LLC
Term
through 2036
9:03 AM ET 8-K
M&A Deal Arcosa, Inc. ACA

Arcosa M&A Deal with CRH Americas, Inc.

Arcosa, Inc. completed its merger with CRH Americas, Inc., a subsidiary of CRH plc, resulting in Arcosa becoming a wholly owned subsidiary of CRH. Under the terms of the agreement, Arcosa stockholders received $150.00 in cash for each share of common stock held. In connection with the closing, Arcosa terminated its $1.4 billion senior secured credit facility and repaid approximately $450.1 million in outstanding obligations.

Counterparty
CRH Americas, Inc.
9:01 AM ET 8-K
Licensing Deal Tempus AI, Inc. TEM

Tempus AI Licensing Deal with Bristol-Myers Squibb Company Worth $192M

Tempus AI entered into a series of agreements with Bristol-Myers Squibb (BMS) and Pathos AI to expand the use of its de-identified multimodal real-world data and analysis tools. The deal provides for aggregate cash payments to Tempus of $192.5 million over approximately five years, including $137.5 million for oncology data services to BMS and $55 million for neurology data and agentic tools to Pathos to support BMS's therapeutic development.

Value
$192M
Counterparty
Bristol-Myers Squibb Company
Term
5 years
9:00 AM ET 8-K
Other 8-K Filing Kustom Entertainment, Inc. KUST

Kustom Entertainment Other 8-K Filing

Kustom Entertainment, Inc. filed a Certificate of Amendment to its Articles of Incorporation to increase its total authorized capital stock from 11,333,334 shares to 1,200,000,000 shares. The new authorization includes 1,000,000,000 shares of common stock and 200,000,000 shares of preferred stock, following approval by stockholders at the 2026 annual meeting.

9:00 AM ET 8-K
Stock Buyback Sierra Bancorp BSRR

Sierra Bancorp Stock Buyback Update

Sierra Bancorp's Board of Directors authorized a new share repurchase program for up to 1,000,000 shares of common stock, effective from November 1, 2026, through October 31, 2027. Additionally, the company declared its 111th consecutive quarterly cash dividend of $0.27 per share, payable on November 9, 2026.

Term
through Oct 2027
8:55 AM ET 8-K
Investor Presentation Worthington Enterprises, Inc. WOR

Worthington Enterprises Investor Presentation

Worthington Enterprises announced that its CEO Joe Hayek and CFO Colin Souza will present at the Baird 2026 Global Industrial Conference on November 12, 2026. Additionally, the company will host an Investor and Analyst Day in New York City on November 10, 2026, to provide updates on its strategy, financial performance, and long-term growth opportunities.

8:52 AM ET 8-K
M&A Deal Crh Public Ltd Co CRH

Crh Public Ltd Signs $8.5B M&A Deal with Arcosa, Inc.

CRH completed its acquisition of Arcosa, Inc., a leading U.S. provider of aggregates and critical infrastructure products, for an enterprise value of approximately $8.5 billion. The deal reinforces CRH's position as the top infrastructure player in North America and increases its exposure to major road, water, energy, and data projects.

Value
$8.5B
Counterparty
Arcosa, Inc.

“Arcosa is an excellent strategic fit for CRH and fully aligns with our growth ambitions. With high-quality aggregates assets and attractive positions in the growing U.S. energy transmission market, the acquisition strengthens our connected portfolio and reinforces our position as the #1 infrastructure player in North America. We look forward to welcoming our Arcosa colleagues into CRH and executing on the strong growth opportunities ahead.”

Jim Mintern, CRH CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.